Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

By P. Fong, D. Boss, T. Yap, Andrew Tutt, P. Wu, M. Mergui-Roelvink, Peter S. Mortimer, H. Swaisland, A. Lau, Mark J. O'Connor and 5 more. New England Journal of Medicine, 2009

3,580 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/7a8f00d4183e6dbe5ac40046840b01ca5cdbebc1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

In Reproductive Medicine

Citations in the corpus

NAD+ metabolism and the control of energy homeostasis - a balancing act between mitochondria and the nucleus (2015, background): “As a result, PARP inhibition can be an effective treatment for cancer (Bryant et al., 2005; Farmer et al., 2005; Fong et al., 2009), leading to the development of several potent PARP inhibitors as chemotherapeutic agents.”
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets (2010, positive): “8), in breast and ovarian cancers containing BRCA1 and BRCA2 mutations at safely administrable doses with minimal side-effects (Fong et al., 2009).”
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. (2012, background): “Phase I studies evaluating olaparib (AZD2281) as monotherapy in breast cancer with BRCA1 and BRCA2 mutations show a very high response rate and clinical benefit (47% and 63%, respectively).(42)”
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. (2010, background): “There were no obvious differences in the pattern of toxicities experienced by patients with BRCA1 or BRCA2 mutated ovarian cancer or between BRCA and non-BRCA mutation carriers.(17)”
A decade of clinical development of PARP inhibitors in perspective (2019, methodology): “A first-in-human clinical trial of KU-0059436 (KuDOS Pharmaceuticals/ AstraZeneca, later named AZD-2281/olaparib) was conducted to establish a recommended dose and to generate preliminary data in a biomarker-defined population [6, 7].”
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. (2017, background): “9 pp 2–5, 7, 18).(7) Patients were classified into one of three predefined HRD subgroups based on tumour analysis: BRCA mutant (deleterious germline or somatic), BRCA wild-type/LOH high, or”
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors (2009, positive): “These tumour responses, demonstrated by both radiological estimation of tumour size and by the use of biochemical markers of tumour burden, are sustained and can be achieved without the signiﬁcant toxicity normally associated with standard chemotherapeutic regimes (Fong et al, 2009).”